Home › Compare › LCCTF vs ABBV
LCCTF yields 0.67% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, LCCTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LCCTF + ABBV for your $10,000?
L'Occitane International S.A., together with its subsidiaries, designs, manufactures, and retails various natural and organic ingredient-based cosmetics and well-being products. It offers perfumes, soaps, and fragrant products. The company also provides skincare, haircare, body and bath, makeup, floral water, beauty oils, and other products. In addition, it engages in the general warehousing business. The company markets and sells its products under the L'OCCITANE en Provence, Melvita, Erborian, L'Occitane au Brésil, LimeLife by Alcone, ELEMIS, and Sol de Janeiro brand names to final customers, as well as intermediates, such as distributors, wholesalers, TV show channels, and travel retailers. As of March 31, 2022, it operated 3,068 retail locations with 1,490 own retail stores. It also sells its products through online. L'Occitane International S.A. has operations in Japan, the United States, Hong Kong, China, France, Russia, the United Kingdom, Russia, Luxembourg, Brazil, Taiwan, and internationally. The company was founded in 1976 and is headquartered in Luxembourg City, Luxembourg. L'Occitane International S.A. is a subsidiary of L'Occitane Groupe S.A.
Full LCCTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.